The purpose of Core A (Administrative Core) is to provide the organizational framework to optimally implement an HIV Vaccine Research and Design (HIVRAD) Program to design and develop an efficacious HIV/AIDS prophylactic vaccine based on Cytomegalovirus (CMV) vectors. This framework will provide scientific leadership and integration ofthe Program, as well as administrative support and assistance to the Program Director and Project Leaders. This includes providing logistical support on administrative and clerical matters, facilitating interactions between Project and Core Leaders and providing a forum for decision making, database maintenance and administration, data sharing, experimental planning, manuscript writing and submission, progress report submission, financial tracking and management, as well as organizing an external speakers program and external scientific advisary board to evaluate the progress and overall direction of the program.
The specific aims of this Core are to: 1. To ensure an interactive environment and foster a cohesive, focused relationship among Program scientists and to provide a forum for Project and Core Leaders to set overall priorities and make key decisions via regular meetings and videoconferences. 2. To promote scientific advancement of the Program by inviting external speakers in the areas of HIV/AIDS vaccines, viral immunology and CMV pathobiology and by establishing an external scientific advisory board (eSAB) to review the progress ofthe program, and provide independent scientific oversight. 3. To provide fiscal oversight and general administrative, budgetary, database, and statistical support for the overall program. 4. To maintain communication with the NIAID program officer and other NIAID staff, coordinate reports to the NIH and eSAB and ensure compliance with NIH and local institutional requirements.
The main goal ofthis Core is to support and assist the Program Director and investigators in their integrated efforts to design and develop a safe and effective prophylactic effector-memory T cell vaccine against HIV/AIDS.
|Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137|
|Child, Stephanie J; Hickson, Sarah E; Bayer, Avraham et al. (2018) Antagonism of the Protein Kinase R Pathway in Human Cells by Rhesus Cytomegalovirus. J Virol 92:|
|McMichael, Andrew J; Picker, Louis J (2018) Corrigendum to 'Unusual antigen presentation offers new insight into HIV vaccine design' [Curr Opin Immunol 46 (2017) 75-81]. Curr Opin Immunol 53:217|
|Wu, Helen L; Wiseman, Roger W; Hughes, Colette M et al. (2018) The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. J Immunol 200:49-60|
|Früh, Klaus; Picker, Louis (2017) CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination. Curr Opin Immunol 47:52-56|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Hansen, Scott G; Wu, Helen L; Burwitz, Benjamin J et al. (2016) Broadly targeted CD8? T cell responses restricted by major histocompatibility complex E. Science 351:714-20|
|Hansen, Scott G; Sacha, Jonah B; Hughes, Colette M et al. (2013) Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340:1237874|
|Hansen, Scott G; Piatak Jr, Michael; Ventura, Abigail B et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502:100-4|
|Masopust, David; Picker, Louis J (2012) Hidden memories: frontline memory T cells and early pathogen interception. J Immunol 188:5811-7|
Showing the most recent 10 out of 11 publications